Lawrence Otto Klein - 23 Jan 2026 Form 4 Insider Report for Oruka Therapeutics, Inc. (ORKA)

Role
Chief Executive Officer, Director
Signature
/s/ Paul Quinlan, as attorney-in-fact for Lawrence Klein
Issuer symbol
ORKA
Transactions as of
23 Jan 2026
Net transactions value
$0
Form type
4
Filing time
23 Jan 2026, 17:38:52 UTC
Previous filing
01 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Klein Lawrence Otto Chief Executive Officer, Director C/O ORUKA THERAPEUTICS, INC., 855 OAK GROVE AVE., SUITE 100, MENLO PARK /s/ Paul Quinlan, as attorney-in-fact for Lawrence Klein 23 Jan 2026 0001762583

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORKA Common Stock Award $0 +76,700 +9% $0.000000 929,038 23 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORKA Employee Stock Option (right to buy) Award $0 +306,700 $0.000000 306,700 23 Jan 2026 Common Stock 306,700 $34.39 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day).
F2 The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.